{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["96(9)"],"submitter":["Klickovic U"],"funding":["Target ALS","Medical Research Council","Brain Research Trust","Motor Neurone Disease Association","UCLH NIHR Biomedical Research Centre"],"pubmed_abstract":["<h4>Background and objectives</h4>Quantitative and operator-independent biomarkers of disease progression are urgently needed in amyotrophic lateral sclerosis (ALS) research. We assess the potential of skeletal muscle MRI as a sensitive and reliable outcome measure for future ALS clinical trials.<h4>Methods</h4>In this longitudinal cohort study, muscle MRI of head-neck, upper and lower limb regions, alongside clinical and functional assessments, were acquired at three time points over the individual maximum observation period (iMOP) of 1 year in 20 patients with ALS and 16 healthy controls. Quantitative MRI parameters cross-sectional area (CSA), volume (VOL), fat fraction, functional rest muscle area and water T2 (T<sub>2m</sub>) were correlated with changes in clinical disease severity (f"],"journal":["Journal of neurology, neurosurgery, and psychiatry"],"pagination":["908-911"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12418527"],"repository":["biostudies-literature"],"pubmed_title":["Muscle MRI quantifies disease progression in amyotrophic lateral sclerosis."],"pmcid":["PMC12418527"],"pubmed_authors":["Morrow JM","Zafeiropoulos N","Dudziec M","Sharma N","Malaspina A","Zampedri L","Ziff OJ","Trimmel K","Sidle KC","Shah S","Fratta P","Thornton JS","Greensmith L","Klickovic U","Wastling S","Yousry TA","Allen J","Nasel C","Sinclair CD","Howard RS"],"additional_accession":[]},"is_claimable":false,"name":"Muscle MRI quantifies disease progression in amyotrophic lateral sclerosis.","description":"<h4>Background and objectives</h4>Quantitative and operator-independent biomarkers of disease progression are urgently needed in amyotrophic lateral sclerosis (ALS) research. We assess the potential of skeletal muscle MRI as a sensitive and reliable outcome measure for future ALS clinical trials.<h4>Methods</h4>In this longitudinal cohort study, muscle MRI of head-neck, upper and lower limb regions, alongside clinical and functional assessments, were acquired at three time points over the individual maximum observation period (iMOP) of 1 year in 20 patients with ALS and 16 healthy controls. Quantitative MRI parameters cross-sectional area (CSA), volume (VOL), fat fraction, functional rest muscle area and water T2 (T<sub>2m</sub>) were correlated with changes in clinical disease severity (f","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-06-02T00:20:44.677Z","creation":"2026-05-24T03:07:40.786Z"},"accession":"S-EPMC12418527","cross_references":{"pubmed":["40132878"],"doi":["10.1136/jnnp-2024-335571"]}}